Single-Dose HIV Vaccine Breakthrough: Dual Adjuvants Trigger Strong Immune Response

Researchers at MIT and the Scripps Research Institute have demonstrated that a single vaccine dose, enhanced with two powerful adjuvants, can elicit a strong immune response against HIV. In mice, this dual-adjuvant approach generated significantly more diverse antibodies compared to vaccines with a single adjuvant or no adjuvant. The vaccine lingered in lymph nodes for up to a month, allowing for the generation of a greater number of antibodies. This strategy holds promise for developing single-dose vaccines for various infectious diseases, including HIV and SARS-CoV-2.